Skip to main content

Teleflex Inc(TFX-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

New Data Reinforce Efficacy of the UroLift® System for the Treatment of Enlarged Prostate

Globe Newswire - Fri Jul 1, 2022

WAYNE, Pa., July 01, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the results of several research studies that further support the safety and efficacy of the UroLift® System for men living with enlarged prostate, or benign prostatic hyperplasia (BPH), including among those who have a wide range of prostate sizes and/or a median lobe obstruction. The data will be presented at the 37th Annual European Association of Urology (EAU) Congress in Amsterdam and virtually.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe